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Background: The purpose of this study was to investigate the ability of Alzheimer’s disease 
(AD) patients to express intentions and desires, and their decision-making capacity. This study 
examines the findings from a 6-month follow-up of our previous results in which 30 patients 
participated.
Materials and methods: The patient’s cognition was examined by conducting the tests of 14 
questions and letter-writing ability over a period of 19 days, and it was repeated after 6 months. 
The difference between these two cognitive measures (PQ1 before–PQ2 before), tested previ-
ously and later the writing test, was designated DΔ before. The test was repeated after 6 months, 
and PQ1 after–PQ2 after was designated DΔ after.
Results: Several markedly strong relationships between dysgraphia and other measures of 
cognitive performance in AD patients were observed. The most aged patients (over 86 years), 
despite less frequency, maintain the cognitive capacity manifested in the graphic expressions. 
A document, written by an AD patient presents an honest expression of the patient’s intention 
if that document is legible, clear, and comprehensive.
Conclusion: The identification of impairment/deficits in writing and cognition during different 
phases of AD may facilitate the understanding of disease progression and identify the occasions 
during which the patient may be considered sufficiently lucid to make decisions.
Keywords: cognition, intentions, unfit to plead, consent
Introduction
Alzheimer’s disease (AD) is an incurable and devastating neurodegenerative disease 
with progressive cognitive, functional, behavioral, and neuropathological changes,1,2 and 
it affects .30 million people worldwide, which is expected to be tripled by 2050.3,4
Studies have shown that writing may identify a specific deficit in AD patients and its 
deterioration can be related to the pathological changes5–7 and the further deterioration 
of cognitive functions.8,9 Other strong relationships were observed between dysgraphia 
and cognitive performance (PQ1) in AD patients’ marked deterioration.10
Moreover, floating attention, cognition, and writing skills have been observed in these 
patients. Between the two extremes, good health and absolute cognitive impairment, there 
exist a whole series of intermediate states with alternating phases of aggravation with loss 
of cognition and remission phases when the patient may have the capacity to understand, 
to make decisions, and express intentions. Thus, even if a person has AD, diagnosis 
cannot be equated with decisional incapacity.11 Nevertheless, it is essential to distinguish 
between patients and episodes on the basis of functionality and nonfunctionality.
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As long as must, the AD patient is deemed capable to 
intentions and wishes it is necessary to make provisions for 
those results expressed on previous documents.
The present study examines the findings from a 6-month 
follow-up of our previous results in which 30 patients 
participated.12 The purpose was to measure the patients’ 
cognitive performance and the episodes during which the 
patients with serious AD may be considered sufficiently 
lucid to make decisions.
Materials and methods
Participants
Twenty-seven AD patients (6 months later from previous 
Onofri et al study) were selected to participate in the study: 
13 males and 14 females. The previous number of 30 patients 
was reduced by three since these patients died. All the patients 
were presenting symptoms that indicated a diagnosis of AD 
from moderate-to-relatively severe level (mini-mental state 
examination [MMSE] range: 10.1–16.7).
The diagnoses according to the National Institute of 
Neurological and Communicative Disorders and Stroke, the 
Alzheimer’s Disease and Related Disorders Association,13 
and the Diagnostic and Statistical Manual of Mental Dis-
orders, 4th edition reference, were confirmed by resident 
neurologists of the Department of Neurology at the hospitals 
(Gemelli University Polyclinic-service neuropsychology, 
Rome, Italy, and the Alzheimer Evaluation Unit ASLRMF 
and Alzheimer Evaluation Unit ASLRMD, and Department 
of Neurology and Psychiatry, Sapienza Hospital, Rome, 
Italy) in the Lazio region.
The mean MMSE score ± standard deviation (SD) was 
14.11±1.74 (male) and 13.4±2.27 (female). The control group 
of age- and education-matched healthy senior citizens was 
chosen as individuals who were not, in any way, influenced 
by AD and who presented the following characteristics: mean 
age 82.73 years (SD ±5.7 years). The mean amount of time 
spent upon education by the healthy controls was 12.8 years 
(SD ±4.04 years). The ethical review board of the Local Health 
Unit RM F of Lazio deemed ethical approval not necessary 
for this study. All principles outlined in the Declaration of 
Helsinki were followed. Written informed consent was obtained 
from subjects and patients or their relatives. All patients were 
examined by clinicians.
Procedure
The details of the methodology have been previously 
described in depth;12 therefore, they will be summarized 
here.
A standard collection of 14 simple questions were given 
to the patients. For each correct answer, one point was 
attributed in proportion to the difficulty of the question. 
The sum of each test session was represented by PQ1 before 
(PQ1B). Following this, each patient was invited to write a 
letter to a close relative. The letter-writing task was inter-
rupted when it seemed that the text written by the patient was 
substantially (pathologically) confusing (when the phrase 
offered no conceptual association with accompanying text 
although in the presence of otherwise “correct” syntax and 
when it had a sudden lack of readability, disjointedness, and 
incompleteness in meaning with intrusions, semantic substi-
tutions, alterations in the spatial organization of handwriting, 
illegible words, incidence of paraphrases, incapacity to form 
complete sentences, graphemic substitutions [a grapheme 
is the smallest semantically distinguishing unit in a written 
language], omissions, and additions).
The patient’s writing test was evaluated by two experts 
(physician and lawyer) who evaluated each AD patients’ 
letter writing equally. After this, using a chronometer, the 
number of minutes that had been reached for each single 
patient was registered, and the complete sentences were 
counted (sentences/minutes = XF before [XFB]). The whole 
procedure involving the letter-writing graphia task was inter-
rupted after 20 minutes.
The list of 14 questions given to the patients in PQ1B 
was also given to the patients in a repeated procedure that 
was designated PQ2 before (PQ2B). The difference between 
these two measures (PQ1B–PQ2B) was designated DΔ 
before. These procedures for testing, graphia test, 14-item 
test, were presented in an identical manner every second 
day over 10 days (days 1, 3, 5, 7, 9, 11, 13, 15, 17, and 
19) at the same hour of day on test days to hold constant 
testing procedures over daily curriculum and any clinical 
interventions that the patients may be subjected to. These 
procedures for testing were presented in an identical man-
ner after 6 months. The answers to the questionnaire before 
the written test were designated PQ1 after (PQ1A), and 
the answers to the questionnaire after the written test were 
designated PQ2 after (PQ2A); DΔ after was the difference 
between PQ1A and PQ2A (PQ1A–PQ2A).
statistical analysis
Mean and SD were used to calculate PQ1B/A and PQ2B/A 
scores and XFB/A and DΔB/A of the AD patients and the 
healthy control group over consecutive days of testing. 
Scheffe’s test was used to make unplanned comparisons of 
group mean of test days 1–9 with that of days 11–19.
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Results
The clinical characteristics of the participants in the study 
are presented in Table 1.
The cognitive performance of the AD patients deteriorated 
from PQ1B to PQ1A, and the XF value deteriorated before 
and after. The deterioration from PQ1A to PQ2A (DΔA) was 
significantly impaired as compared with DΔB (Table 2).
Figure 1 shows a 6-month follow-up of AD patients’ 
dysgraphia and cognitive dysfunction.
Patients were divided into three age-groups, 73–79 years 
(aged), 80–85 years (elder aged), and .86 years (eldest aged) 
(Figures 2–4).
Discussion
This study examines cognitive process in AD patients and the 
relationships between initial cognitive performance (PQ1B), 
the deterioration in cognitive performance following a letter-
writing task (PQ1B − PQ2B = DΔB), and XFB in a group 
of AD patients presenting a moderate-to-relatively severe 
stage of disorder and comparing with cognitive performance 
in the same group of patients observed after 6 months. Both 
the correlations between PQ1B and PQ2B over all test days 
and the deterioration of performance from PQ1A to PQ2A 
over all test days were marked. The relationships between 
initial cognitive performance (PQ1B/A) and extent and XF 
over both patients and test days were markedly impaired. The 
relationships between dysgraphia and cognitive deterioration 
(DΔB/A) were also markedly strong. A comparison of AD 
patients vs control patients are shown in Figure 5.
AD involves disorders of the memory17 as well as of 
other cognitive functions18 and leads to a progressive overall 
deterioration of the intellect and personality,19,20 and it raises 
Table 1 Clinical and neuropsychological characteristics of AD 
patient groups in this study
Male (n=13) Female (n=14)
Mean age (years) 77.22± sD 1.78 82.22± sD 2.04
educational (years) 11.11± sD 2.5 12.77± sD 3.8
Apraxia (%) 88.8 77.7
Aphasia (%) 88.8 88.8
Agnosia (%) 22.2 33.3
MMsea (mean) M 14.11± sD 1.74 M 13.4± sD 2.27
ADlb 4.22± sD 0.44 3.88± sD 0.92
IADlc 4± sD 0 2.66± sD 1
Beginning of the disease (years) 4.11± sD 0.92 4.55± sD 1.13
Notes: aMMse14 (normal level score =30 points), modified by age and education. 
bADls15 (normal level =6/6 for both males and females). cIADls16 (normal level =8/8 
for both males and females).
Abbreviations: AD, Alzheimer’s disease; ADls, activities of daily living; IADls, 
instrumental activities of daily living; MMse, mini-mental state examination; sD, 
standard deviation; M, mean.
Table 2 The performance of AD patients on the tests of cognition, PQ1B and PQ1A, the difference between PQ1 before and PQ2 
before (DΔ before), and the difference between PQ1 after and PQ2 after (DΔ after) and on the writing test before and after
Days of testing PQ1Ba PQ1Ab DΔB DΔA XFBc XFAd Number of patients
Day 1 12.18±4.9 6.07±5.9 8.11±4.9 3.74±4.7 9.25±6.7 2.77±3.8 27
Day 3 10.37±4.4 8.77±4.3 6.25±3.1 4.59±3.8 8.07±5.1 4.11±4.4 27
Day 5 9.51±5.2 7.51±4.6 5.1±4.0 3.77±3.9 7.74±7.0 3.18±3.9 27
Day 7 9.29±4.8 5.96±3.8 4.18±3.1 2.29±3.3 5.74±5.5 1.40±2.7 27
Day 9 11.96±3.1 6.07±4.4 6.44±2.7 2.59±3.8 8.11±6.0 2.0±3.8 27
Mean days 1–9 10.66±4.6 6.73±4.8 6.03±3.8 3.06±3.9 7.78±6.1 2.69±3.8 27
Day 11 8.48±4.4 6.18±3.1 3.59±2.5 1.96±3.0 4.74±5.15 1.55±3.5 27
Day 13 8.81±4.3 6.88±3.8 3.44±3.0 2.88±3.1 5.11±5.8 1.74±2.8 27
Day 15 8.62±4.5 6.29±3.4 3.8±2.9 2.59±3.0 5.11±5.5 1.77±3.1 27
Day 17 9.29±4.2 6.92±3.8 4.1±2.6 2.74±3.5 6.44±5.5 1.81±2.7 27
Day 19 9.55±5.2 6.11±4.1 5.07±2.8 2.77±3.2 6.96±7.1 2.18±3.6 27
Mean days 11–19 8.95±4.5 6.34±3.7 4.02±2.8 2.33±3.1 5.67±5.8 1.81±3.1 27
Notes: The performance comparisons of the mean of test days 1–9 with that of days 11–19 using scheffé’s test (days 1–9 vs days 11–19): aF (9, 260) =29.70; bF (9, 260) =1.97; 
cF (9, 260) =36.07; and dF (9, 260) =18.61.
Abbreviations: AD, Alzheimer’s disease; DΔA, DΔ after; DΔB, DΔ before; PQ1A, PQ1 after; PQ1B, PQ1 before; XFA, XF after; XFB, XF before; XF, sentences/minutes.
Figure 1 An example of an eldest aged patient.
Note: The peaks represent the moments of skills and good cognitive performance 
and handwriting.
Abbreviation: XF, sentences/minutes.
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the question of impairment of ability to self-determination. 
In comparison with the extrapolated data after 6 months, the 
AD patients demonstrated deficits in initial cognitive perfor-
mance (PQ1B), in dysgraphia, and in DΔB. We have noticed 
that the marked deterioration in the handwriting of AD patients 
is present when the level of the PQ, ie, cognition, is ,11.
Furthermore, the graphs of Figures 2–4 show that the 
most aged patients have a greater loss of cognition than the 
less aged patients. Nevertheless, 6 months later, we note 
that the most aged patients, although with less frequency, 
maintain a level of cognition that may be manifested in the 
graphic gesture (Figure 1).
Low values of PQ2 and fluctuation of cognitive functioning, 
demonstrated with the test repeated for 10 days, confirm the 
hypothesis that the cognitive decrease is not due to diminution 
of number of neurons but due to synaptic modifications.21
Attention, construction, conceptualization, and memory dis-
orders are correlated with AD dysgraphia,22 and with this work, 
we have shown that a document written by an AD patient is an 
honest expression of the patient’s intention, if this document is 
legible, clear, and comprehensive. Indeed, to write a document 
requires not only the ability to program skilled movements23 and 
to represent graphemes but also the integration of memory with 
cognitive processes24 (eg, developing personal thoughts).
Implications
The signature affixed to all legal documents, perfecting and 
making them valid, assumes that the person who has signed 
has the mental capacity and has understood the meaning of 
the document signed.
In AD patients, the apposition of signature is a mechani-
cal process with subcortical anchorage,25 and it is the last 
documental graphic sign that the AD patient is able to put 
in the course of the disease; consequently, the signature is 
not an indicator of understanding of the document on behalf 
of an AD patient.
If legal disputes occur, the documents are cancelable if 
the person who has made them was devoid of capacity when 
he or she issued his or her declaration of intent. Also, persons 
experiencing lucid intervals may be considered competent to 
execute legal document during such periods.
The few legal courts addressing the issue have held 
consistently that AD patients with moderate or relatively 
severe level of impairment are competent or not competent 
to execute legal document based on the testimony of those 
who interacted with the patient.
In this study, we show that the evaluation of a writ-
ten document can be the proof of the AD patients’ ability 
to understand and their will. In this case, if a person with 
dementia is able to write a document that makes complete 
sense, it is presumed he or she likely maintains the legal 
capacity. As long as the AD patient has legal capacity, he 
or she should take part in legal planning.26 Therefore, the 
Figure 2 Comparisons of PQ1 before and PQ1 after of group 1 (aged).
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Figure 4 Comparisons of PQ1 before and PQ1 after of group 3 (eldest aged).
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Figure 3 Comparisons of PQ1 before and PQ1 after of group 2 (elder aged).
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Abbreviations: AD, Alzheimer’s disease; sD, standard deviation; XF, sentences/
minutes.
&RQWURO
$'SDWLHQWV
9DOXHVH[SUHVVHGDVPHDQ$'!FRQWURO
3DWLHQWV
;)
Clinical Interventions in Aging 2016:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
283
legal medical consideration of Alzheimer’s disease patients’ dysgraphia
incapacity of judgment requires the existence of a mental 
disability (objective aspect), which results in the lack of 
capacity to act rationally (subjective aspect). By law, the 
capacity of judgment is assumed (statutory presumption), 
and the opposite has to be proved.27
Documents in which the incapable performs directly are 
temporarily effective, but they can be canceled (resulting in 
elimination of the effects that they have produced) by the 
initiative of his or her legal representative or him- or herself 
(if he or she has obtained the capacity). If legal disputes 
occur, the clinicians make a retrospective assessment of a 
patient’s capacity evaluating patient’s clinical records and 
MMSE. However, some authors imply that the MMSE is 
not an indicator of capacity,28,29 and it cannot be used as 
the only instrument for evaluating the decisional ability,30 
capacity to consent.
Conclusion
To study the cognitive ability in relation to graphia may be 
useful for guiding decisions in everyday practice. Most of the 
available researches have focused on the nature and degree 
of decisional impairment associated with various clinical 
states, including psychiatric,31,32 neurologic,33 and general 
medical34 conditions.
Prior research has shown considerable unexplained vari-
ability in clinicians’ judgments.35 Marson et al36 showed that 
five experienced clinicians evaluating the capacity of AD 
persons are unable to agree.37 In Italy, the ability to provide 
for its own interests is determined by the court with an exami-
nation of the interdicting and is sanctioned by a judgment 
(cd judicial interdiction).
The relatively lower proportion of participants who had 
undergone follow-up assessments is a limitation of this 
study.
Disclosure
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